Partnering
Our proprietary epiQ.bio technology platform enables screening, validation and mechanistic characterization of small molecule modulators of epigenetic actuators and other regulators of gene expression that are controlled by long non-coding RNAs (lncRNAs).
These high-value molecules have transformative potential for the following industries:
Health & Nutrition- Nutraceuticals, Functional Foods & Healthy Aging products
Biotech & Pharma- Therapeutics for aging-related morbidities, degenerative & fibrotic disease
Mission
We enable identification and validation of small molecules targeting epigenetic factors of biological aging programs. Modulation of these actuators can be a preventive safeguarding strategy to bring about health span extension by improving tissue regeneration, lipid metabolism, and inflammatory processes.
These actuators are further involved in tissue degeneration and fibrotic disease controlling hepatocyte senescence, liver fibrosis and age-related cardiac dysfunction.
Assay Platform
Our propietary epiQ.bio technology platform enables identification of small molecules specifically interfering with lncRNA-guided epigenetic actuators and gene expression regulators.
We quantify lncRNA-dependent activity of such epigenetic master regulators of complex biological programs involved in aging, health span, and aging-related disease (read more).
Offerings
epiQ.bio quantitatively assesses biological activity of lncRNA-guided epigenetic actuators and regulators of gene expression by measuring lncRNA:actuator interaction.
This functional assessment can be performed with select molecules, tailored industry-specific molecule libraries, pharmaceutical industry-grade high throughput-screening (HTS) libraries, plant based product & extracts, phytochemical products.
Contact
We can serve various industries from Health & Nutrition to Biotech & Pharma to satisfy your demand for high value molecules with validated mechanism of action and biological and biomedical impact.